Lexaria Bioscience CEO: Faster, Cost-efficient Drug Delivery Platform for COVID-19 and Beyond

Video Interview

Lexaria Bioscience CEO Chris Bunka discusses the technology’s potential to treat viral infections via oral delivery and help save billions in the drug administration process.

Lexaria Bioscience CEO: Faster, Cost Efficient Drug Delivery Platform with Royalty Revenue Modelyoutu.be

Lexaria Bioscience (NASDAQ:LEXX,CSE:LXX) concluded its expanded research program for DehydraTECH-enabled remdesivir and ebastine, showing effective results in inhibiting the COVID-19 SARS-CoV-2 virus. Lexaria Bioscience CEO Chris Bunka discussed the technology’s potential to treat viral infections via oral delivery and help save billions in the drug administration process.

“Our delivery from oral to the bloodstream is at least two minutes. We’re outrageously fast for oral technology. We’ve been able to improve the delivery rates by 35 percent and 45 percent previously reported on December 1, 2020,” said Bunka.

The study shows DehydraTECH™ improves delivery into the bloodstream of orally administered remdesivir and ebastine. The result may be relevant with additional antiviral drugs within their classes for indications including and beyond COVID-19.

“We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill.”

According to Bunka, delivering an antiviral drug that was originally designed for an injectable form through a new oral form could help governments or health insurance companies save billions of dollars just in administration costs.

Watch the full interview with Lexaria Bioscience CEO Chris Bunka above.

This interview is sponsored by Lexaria Bioscience (NASDAQ:LEXX, CSE:LXX). This interview provides information which was sourced by the Investing News Network (INN) and approved by Lexaria Bioscience Corp.in order to help investors learn more about the company. Lexaria Bioscience is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Lexaria Bioscience and seek advice from a qualified investment advisor.

The Conversation (0)